Highlights Merck & Co., Inc.

Equities

MRK

US58933Y1055

Real-time Estimate Cboe BZX Other stock markets 11:51:38 2024-04-30 am EDT			5-day change	1st Jan Change
130.5 ^USD	+0.27%		+2.46%	+19.24%

11:00am	BioMed X Announces the Start of A New Research Project in Partnership with Merck	CI
Apr. 29	Merck Reports Positive Data for Investigational 21-Valent Pneumococcal Vaccine	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioMed X Announces the Start of A New Research Project in Partnership with Merck	05:00am	CI
Merck Reports Positive Data for Investigational 21-Valent Pneumococcal Vaccine	Apr. 29	MT
Blackstone beats Concord with $1.6 bln bid for Hipgnosis Songs	Apr. 29	RE
Habeck's 'pharma trip' - industry sees structural problems	Apr. 29	DP
AbbVie raises annual profit forecast on strong Skyrizi sales	Apr. 26	RE
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump	Apr. 25	MT
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	Apr. 25
The specter of stagflation rears its ugly head again	Apr. 25
Merck Lifts Full-Year 2024 Outlook Following First-Quarter Beat	Apr. 25	MT
Merck raises annual target ranges	Apr. 25	CF
Merck Non-GAAP Earnings, Sales Rise; 2024 Guidance Raised	Apr. 25	MT
(MRK) MERCK & CO. Expects Fiscal Year 2024 EPS Range $8.53 - $8.65	Apr. 25	MT
Earnings Flash (MRK) MERCK & CO. Reports Q1 Revenue $15.78B	Apr. 25	MT
Earnings Flash (MRK) MERCK & CO. Posts Q1 EPS $2.07	Apr. 25	MT
Merck & Co., Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024	Apr. 25	CI
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales	Apr. 25	RE
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
Hipgnosis' bidding war intensifies as Concord hikes offer for Shakira music owner	Apr. 25	RE
Hanmi Pharmaceutical Enters into Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc. to Evaluate BH3120 in Combination with KEYTRUDA®? (pembrolizumab)	Apr. 23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Merck & Co., Inc.

Equities

MRK

US58933Y1055

Highlights

Filters